Mirae Asset Global Investments Co., Ltd. Intellia Therapeutics, Inc. Transaction History
Mirae Asset Global Investments Co., Ltd.
- $22.5 Billion
- Q3 2024
A detailed history of Mirae Asset Global Investments Co., Ltd. transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Mirae Asset Global Investments Co., Ltd. holds 3,674 shares of NTLA stock, worth $61,466. This represents 0.0% of its overall portfolio holdings.
Number of Shares
3,674
Previous 2,880
27.57%
Holding current value
$61,466
Previous $64,000
17.19%
% of portfolio
0.0%
Previous 0.0%
Shares
21 transactions
Others Institutions Holding NTLA
# of Institutions
319Shares Held
88.7MCall Options Held
668KPut Options Held
865K-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl12.3MShares$205 Million2.39% of portfolio
-
Black Rock Inc. New York, NY9.6MShares$161 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.1MShares$152 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT4.8MShares$80.3 Million3.53% of portfolio
-
State Street Corp Boston, MA4.36MShares$73 Million0.0% of portfolio
About Intellia Therapeutics, Inc.
- Ticker NTLA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,011,800
- Market Cap $1.27B
- Description
- Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...